221 results on '"Behrends, Czarina N."'
Search Results
2. Economic Evaluations of Establishing Opioid Overdose Prevention Centers in 12 North American Cities: A Systematic Review
3. Human Immunodeficiency Virus transmission by HIV Risk Group and Along the HIV Care Continuum: A Contrast of 6 US Cities.
4. Attributing health benefits to preventing HIV infections versus improving health outcomes among people living with HIV: an analysis in six US cities.
5. The Potential Epidemiological Impact of Coronavirus Disease 2019 (COVID-19) on the Human Immunodeficiency Virus (HIV) Epidemic and the Cost-effectiveness of Linked, Opt-out HIV Testing: A Modeling Study in 6 US Cities
6. “Ending the Epidemic” Will Not Happen Without Addressing Racial/Ethnic Disparities in the United States Human Immunodeficiency Virus Epidemic
7. Can the 'Ending the HIV Epidemic' initiative transition the USA towards HIV/AIDS epidemic control?
8. Ending the HIV Epidemic Among Persons Who Inject Drugs: A Cost-Effectiveness Analysis in Six US Cities
9. Ending the HIV epidemic in the USA: an economic modelling study in six cities
10. The impact of localized implementation: determining the cost-effectiveness of HIV prevention and care interventions across six United States cities.
11. Development and Calibration of a Dynamic HIV Transmission Model for 6 US Cities
12. Evaluating equity in community-based naloxone access among racial/ethnic groups in Massachusetts
13. Ending the Epidemic in America Will Not Happen if the Status Quo Continues: Modeled Projections for Human Immunodeficiency Virus Incidence in 6 US Cities.
14. Barriers to engaging people who use drugs in harm reduction services during the COVID-19 pandemic: A mixed methods study of syringe services program perspectives
15. Responding to a surge in overdose deaths: perspectives from US syringe services programs
16. Correction: M2HepPrEP: study protocol for a multi-site multi-setting randomized controlled trial of integrated HIV prevention and HCV care for PWID
17. M2HepPrEP: study protocol for a multi-site multi-setting randomized controlled trial of integrated HIV prevention and HCV care for PWID
18. Harm reduction and health services provided by syringe services programs in 2019 and subsequent impact of COVID-19 on services in 2020
19. Participants of a mail delivery syringe services program are underserved by other safe sources for sterile injection supplies
20. Targeting community-based naloxone distribution using opioid overdose death rates: A descriptive analysis of naloxone rescue kits and opioid overdose deaths in Massachusetts and Rhode Island
21. Syringe Service Program Perspectives on Barriers, Readiness, and Programmatic Needs to Support Rollout of the COVID-19 Vaccine
22. Impact of Removing Medicaid Fee-for-Service Hepatitis C Virus (HCV) Treatment Restrictions on HCV Provider Experience with Medicaid Managed Care Organizations in New York City
23. A Harm Reduction Approach to Treating Opioid Use Disorder in an Independent Primary Care Practice: a Qualitative Study
24. Impact of routine opt-out HIV/HCV screening on testing uptake at a syringe services program: An interrupted time series analysis
25. Ending the HIV epidemic in the USA: an economic modelling study in six cities
26. Estimated impact of supervised injection facilities on overdose fatalities and healthcare costs in New York City
27. Addressing Barriers to On-site HIV and HCV Testing Services in Methadone Maintenance Treatment Programs in the United States: Findings From a National Multisite Qualitative Study
28. Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs
29. NEXT: description, rationale, and evaluation of a novel internet-based mail-delivered syringe service program.
30. Evaluation of Routine HIV Opt-Out Screening and Continuum of Care Services Following Entry into Eight Prison Reception Centers — California, 2012
31. Availability of HIV and HCV On-Site Testing and Treatment at Syringe Service Programs in the United States
32. A Cost Reimbursement Model for Hepatitis C Treatment Care Coordination
33. NEXT: description, rationale, and evaluation of a novel internet-based mail-delivered syringe service program
34. Comparing Projected Fatal Overdose Outcomes and Costs of Strategies to Expand Community-Based Distribution of Naloxone in Rhode Island
35. Availability of and Obstacles to Providing COVID-19 Vaccinations at Syringe Services Programs in the United States, 2021
36. Modeling the cost‐effectiveness and impact on fatal overdose and initiation of buprenorphine–naloxone treatment at syringe service programs
37. Human Immunodeficiency Virus transmission by HIV risk group and along the HIV care continuum: A contrast of six US cities
38. Additional file 1 of M2HepPrEP: study protocol for a multi-site multi-setting randomized controlled trial of integrated HIV prevention and HCV care for PWID
39. Additional file 2 of M2HepPrEP: study protocol for a multi-site multi-setting randomized controlled trial of integrated HIV prevention and HCV care for PWID
40. Human Immunodeficiency Virus transmission by HIV Risk Group and Along the HIV Care Continuum: A Contrast of 6 US Cities
41. Costs of Opioid Overdose Education and Naloxone Distribution in New York City
42. The Experience of Implementing a Low-Threshold Buprenorphine Treatment Program in a Non-Urban Medical Practice
43. Community‐based naloxone coverage equity for the prevention of opioid overdose fatalities in racial/ethnic minority communities in Massachusetts and Rhode Island
44. Syringe Service Program Perspectives on Barriers, Readiness, and Programmatic Needs to Support Rollout of the COVID-19 Vaccine.
45. The Potential Epidemiological Impact of Coronavirus Disease 2019 (COVID-19) on the Human Immunodeficiency Virus (HIV) Epidemic and the Cost-effectiveness of Linked, Opt-out HIV Testing: A Modeling Study in 6 US Cities
46. The potential epidemiological impact of COVID-19 on the HIV/AIDS epidemic and the cost-effectiveness of linked, opt-out HIV testing: A modeling study in six US cities
47. Community‐based naloxone coverage equity for the prevention of opioid overdose fatalities in racial/ethnic minority communities in Massachusetts and Rhode Island.
48. M2HepPrEP: study protocol for a multi-site multi-setting randomized controlled trial of integrated HIV prevention and HCV care for PWID.
49. Dissemination Science to Advance the Use of Simulation Modeling: Our Obligation Moving Forward
50. Impact of Removing Medicaid Fee-for-Service Hepatitis C Virus (HCV) Treatment Restrictions on HCV Provider Experience with Medicaid Managed Care Organizations in New York City
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.